Inactivated Polio Vaccine Development for Technology Transfer Using Attenuated Sabin Poliovirus Strains to Shift From Salk-IPV to Sabin-IPV
Even after polio eradication, countries will need to continue immunization against poliomyelitis to prevent the risk of a global outbreak due to accidental or deliberate re-introduction of the virus. Following the demonstration of a proof-of-principle in the 1990s and responding to the World Health Organization's call for new polio vaccines, the Netherlands Vaccine Institute developed an inactivated poliovirus vaccine (IPV) based on attenuated "Sabin" poliovirus strains that is formalin-inactivated and injectable. In this article, published in Vaccine, the authors present a short history of one of the first cell-culture based large-scale biological production processes and the roadmap towards the development of Sabin-IPV. They also address future directions and perspectives on the vaccine and its use. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author(s): Bakker WA, Thomassen YE, van't Oever AG, et al.
Visit web page (English)
(Located at www.sciencedirect.com)
Citation: Bakker WA, Thomassen YE, van't Oever AG, et al. Inactivated Polio Vaccine Development for Technology Transfer Using Attenuated Sabin Poliovirus Strains to Shift From Salk-IPV to Sabin-IPV. Vaccine. 2011;29(41):7188-7196.